Review Article

Efficacy and Safety of Xinyue Capsule for Coronary Artery Disease after Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Table 1

Characteristics of included XYC RCTs for CAD after PCI.

Study IDSample size (T/C)Age (year, T/C)Interventions (T/C)DurationOutcomes

Cao et al. [17]272/290(58.92 ± 11.21)/(59.11 ± 11.36)XYC + CWMT/CWMT6 months①②④
Chen et al. [18]45/45(62.03 ± 12.23)/(61.25 ± 13.46)XYC + Fufang Chuanxiong capsule + CWMT/CWMT6 months
Du et al. [19]60/62(63.20 ± 9.20)/(60.02 ± 10.10)XYC + CWMT/CWMT6 months②③
Liu et al. [20]50/50(45∼75)/(47∼75)XYC + CWMT/CWMT6 months①②③
Liu [21]50/50(61.68 ± 7.64)/(62.78 ± 8.60)XYC + Fufang Chuanxiong capsule + CWMT/CWMT6 months①②③
Guo et al. [22]530/524(59.95 ± 9.41)/(60.40 ± 9.64)XYC + CWMT/CWMT + Placebo24 weeks①④⑤
Wang et al. [23]404/404(31∼75)/(35∼75)XYC + Fufang Chuanxiong capsule + CWMT/CWMT6 months①⑤
Zhang et al. [24]40/39(48.03 ± 7.59)/(46.83 ± 6.38)XYC + Fufang Chuanxiong capsule + CWMT/CWMT6 months
Zhao [25]32/32(55.75 ± 12.40)/(57.30 ± 11.89)XYC + CWMT/CWMT + Placebo24 weeks②③④

T/C, treatment/control; CWMT, conventional western medicine treatment; XYC (SFDA registry number: Z20030073), two capsules orally, three times daily; Fufang Chuanxiong capsule (SFDA registry number: 0802205), two capsules orally, three times daily; ① primary cardiovascular events; ② heart function; ③ NT-pro-BNP; ④ quality of life; ⑤ adverse reaction.